Treatment of High-Grade Resectable Osteosarcoma in Patients Over 40 Years
Adults over 40 presenting with a high-grade, resectable osteosarcoma constitute a distinct clinical sub-group. Age is a recognised factor shaping regimen selection, and the evidence-based framework for this population is outlined here.
Clinical Scenario
Conventional osteosarcoma is always high-grade. This protocol applies to patients aged over 40 years with a high-grade primary tumour that is resectable. The patient’s age directly informs regimen selection in this setting, distinguishing management from protocols used in younger cohorts.
Treatment Approach (partial summary)
Curative management integrates systemic chemotherapy with definitive surgery. The approach includes a preoperative chemotherapy phase — designed to facilitate surgical planning and allow assessment of tumour response — followed by wide resection with limb salvage pursued where feasible, aiming for clear surgical margins, and then further systemic treatment. The specific regimen for patients over 40, the full sequencing, and criteria for managing pulmonary disease are detailed in the structured protocol.
Key response criterion: Histological assessment of the surgical specimen evaluates treatment response. A finding of 90% or greater tumour necrosis on the resected specimen indicates a good histological response to preoperative chemotherapy.
References
DOI: 10.1016/j.annonc.2021.08.1995
- Conventional osteosarcoma is always high-grade.
- In patients >40 years, preferred regimens combine doxorubicin, cisplatin and ifosfamide [III, B].
- Curative treatment of high-grade osteosarcoma consists of ChT and surgery [II, A].
- Most current protocols for localised disease include a period of preoperative ChT, to facilitate local surgical treatment and to allow the assessment of histological response, although there is no evidence to support a change in ChT based on this alone.
- Primary metastatic osteosarcoma patients may be treated with a curative intent following the same principles as applied in non-metastatic osteosarcomas.
- In osteosarcoma, a cut-off value of 10% viable tumour cells or 90% response is used to indicate a good response.
View source ↗